Irhythm Technologies Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Jason Mills reiterated a Buy rating on Irhythm Technologies (NASDAQ: IRTC) today and set a price target of $34. The company’s shares closed last Friday at $29.99.

According to TipRanks.com, Mills is a 4-star analyst with an average return of 2.1% and a 51.1% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $32.

The company has a one year high of $32.64 and a one year low of $22.16. Currently, Irhythm Technologies has an average volume of 160.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

iRhythm Technologies, Inc. is a commercial-stage digital healthcare company engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It provides ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. It also offers ZIO Service improves physician management and diagnosis of arrhythmias by providing a wearable biosensor, curating, and analyzing voluminous ECG data. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.